Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer / 肿瘤防治研究
Cancer Research on Prevention and Treatment
;
(12): 191-194, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-986702
ABSTRACT
HER2 is a tyrosine kinase receptor. It is the main drug target and clinical biomarker for the treatment of breast cancer. About 2% of breast cancer cases has HER2 mutations. Regardless of the expression level or amplification status of HER2, breast cancer with HER2 mutations may respond to targeted HER2 therapy. This article reviews the research progress of HER2 gene mutation in the treatment of breast cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research on Prevention and Treatment
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS